case report aspiration glp-1 receptor agonist anesthesia 2023 🔸 Should RAs be continued preprocedurally? 🔸 Who should stop a GLP-1 RA preoperatively? 🔸 Which patients should have their procedures postponed? Read: https://doi.org/10.1097/01.ASM.0001125664.22893.9f Glucagon-Like Peptide-1 Receptor Agonists Do

We also describe the development of incretin-based pharmacotherapy, starting with exendin- 4 and ending with the identification of multi-incretin hormone receptor agonists, which appear to be the next major step in the fight against T2DM and obesity

Learn about GLP-1 agonists, what they can help treat, and how they work to promote weight loss

Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma

Some potential concerns with long-term use of synthetic drugs include: Digestive discomfort (nausea, bloating, diarrhea) Possible nutrient absorption issues over time The need for ongoing injections or high-cost prescriptions Unknown effects from long-term artificial hormone stimulation Natural herbs and whole-food extracts work differentlythey support the bodys own GLP-1 production and related digestive functions rather than replacing or overriding them

Unrealised Expectations Despite progress, several anticipated 2025 milestones did not come to fruition: Regulatory progress stalled: FDAs obesity drug guidance, published in draft form in January 2025, remains unfinalised, whilst EMA has yet to update its 2016 guideline